Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Jan 14, 2022
- Accession no.
- 0001209191-22-003402
- Filed
- Jan 14, 2022
- Trade date
- Dec 28, 2021-Jan 14, 2022
- Filing delay
- 17 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market sales total $4.69M. It was filed 17 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 13, 2022 | Class A Common Stock | CConversionAcquired | +87,000 | $0.00 | $0 | 110,470 | Direct | |
| Jan 13, 2022 | Class A Common Stock | SSaleDisposed | −78,206 | $14.26F3 | −$1,115,217.56 | 32,264 | Direct | |
| Jan 13, 2022 | Class A Common Stock | SSaleDisposed | −8,794 | $14.96F4 | −$131,558.24 | 23,470 | Direct | |
| Jan 14, 2022 | Class A Common Stock | CConversionAcquired | +254,000 | $0.00 | $0 | 277,470 | Direct | |
| Jan 14, 2022 | Class A Common Stock | SSaleDisposed | −254,000 | $13.57F5 | −$3,446,780 | 23,470 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 28, 2021 | Class A Common Stock | GGiftDisposed | −75,000 | $0.00 | $0 | 8,119,342 | Direct | |
| Jan 13, 2022 | Class A Common Stock | CConversionDisposed | −87,000 | $0.00 | $0 | 8,032,342 | Direct | |
| Jan 14, 2022 | Class A Common Stock | CConversionDisposed | −254,000 | $0.00 | $0 | 7,778,342 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $13.80 to $14.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $14.80 to $15.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $13.09 to $14.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.